DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

BLA 125388/S-080
BLA 125388/S-081

SUPPLEMENT APPROVAL
PMR FULFILLMENT

Seattle Genetics, Inc.
Attention: Elaine Waller, PharmD, MBA
Senior Vice President, Regulatory Affairs and Clinical Development Operations
21823 30th Drive Southeast
Bothell, WA 98021

Dear Dr. Waller:

Please refer to your Supplemental Biologics License Applications (sBLA), dated February 17, 2015, received February 18, 2015 for Supplement 080, and your sBLA dated February 20, 2015, received February 20, 2015 for Supplement 081, submitted under section 351(a) of the Public Health Service Act for ADCETRIS® (brentuximab vedotin).

We acknowledge receipt of your amendments for supplement 080 dated April 3, 8, 9, 17, 22, 29, and 30; May 29; July 6, 13 (2), 16, and 20; and August 10, 2015.

We acknowledge receipt of your amendment for supplement 081 dated April 24, 2015.

Supplement 080

This Prior Approval supplemental biologics application provides for a new indication for the treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation based on the final study report from Study SGN35-005 entitled, "*Randomized, double-blind, placebo-controlled, multicenter, phase 3 study to compare the safety and efficacy of brentuximab vedotin and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual HL following autologous stem cell transplant (ASCT).*"

Supplement 081

This Prior Approval supplemental biologics application proposes updates to the United States Prescribing Information (USPI) to include the risk of pulmonary toxicity with ADCETRIS use. Specifically, the Highlights, Warnings and Precautions, Section 5.10 Pulmonary Toxicity, Section 6.2 Post Marketing Experience, and Section 17 Patient Counseling Information were modified.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "*SPL Standard for Content of Labeling Technical Qs and As*" at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this BLA, including pending "Changes Being Effected" (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

SUBPART E FULFILLED

We approved this BLA under the regulations at 21 CFR 601 Subpart E for accelerated approval of Biological Products for Serious or Life-Threatening Illnesses. Approval of this supplement (S-080) fulfills your requirement to verify and describe ADCETRIS® (brentuximab vedotin) clinical benefit under 21 CFR 601.41, for the indication classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.

We remind you that the originally approved indication for ADCETRIS for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen, approved on August 19, 2011, remains under accelerated approval.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this biological product for this indication has an orphan drug designation, you are exempt from this requirement.

FULFILLMENT OF POSTMARKETING REQUIREMENT

We refer to your Biologics License Application (BLA) submitted under section 351 of the Public Health Service Act for ADCETRIS® (brentuximab vedotin).

We have received your submission dated February 17, 2015, containing the final report for the following postmarketing requirement listed in the August 19, 2011, approval letter for BLA 125388.

PMR 2521-3 Reversibility/Resolution of drug-induced peripheral neuropathy. Characterize the severity, duration and reversibility of treatment emergent neuropathy in a prospective trial.

The ongoing placebo-controlled AETHERA trial safety results may be utilized to address this PMR.

Phase 3 Trial Completion Date: 12/2013
Phase 3 Trial Final Report Submission Date: 6/2014

We have reviewed your submission and conclude that the above requirement was fulfilled.

We remind you that there are postmarketing requirements and postmarketing commitments listed in the August 19, 2011 approval letter that are still open.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

As required under 21 CFR 601.12(f)(4), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials for your drug product that include representations about your drug product must be promptly revised to make it consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 601.12(a)(4)]. The revisions to your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 601.12(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Toni-Ann Cox, Regulatory Project Manager, at (240) 402-4775.

Sincerely,

{See appended electronic signature page}

Ann T. Farrell, MD
Director
Division of Hematology Products
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ANN T FARRELL
08/17/2015